Peer-reviewed veterinary case report
Ulnar bone cancer in 30 dogs and survival factors
By Sivacolundhu, Ramesh K et al.·Published in Journal of the American Veterinary Medical Association·2013·Department of Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Ulnar osteosarcoma in dogs: 30 cases (1992-2008).
- Species:
- dog
Plain-English summary
A group of 30 dogs with ulnar osteosarcoma, a type of bone cancer affecting the ulna, were treated to understand their survival outcomes. Some dogs underwent surgery, either a partial removal of the ulna or an amputation, while others did not have surgery. Most dogs also received chemotherapy. On average, dogs lived about 463 days after diagnosis, but those with a specific subtype of the cancer had a much shorter survival time. Overall, the treatment options provided good function and low complication rates, indicating that surgery can be beneficial for these dogs.
People also search for: dog bone cancer treatment · ulnar osteosarcoma prognosis · dog amputation recovery time
Abstract
OBJECTIVE: To examine the biological behavior of ulnar osteosarcoma and evaluate predictors of survival time in dogs. DESIGN: Retrospective case series. ANIMALS: 30 dogs with primary ulnar osteosarcoma. PROCEDURES: Medical records were reviewed. Variables recorded and examined to identify predictors of survival time were signalment, tumor location in the ulna, tumor length, serum alkaline phosphatase activity, surgery type, completeness of excision, tumor stage, tumor grade, histologic subtype, development of metastases, and use of chemotherapy. RESULTS: 30 cases were identified from 9 institutions. Eleven dogs were treated with partial ulnar ostectomy and 14 with amputation; in 5 dogs, a resection was not performed. Twenty-two dogs received chemotherapy. Median disease-free interval and survival time were 437 and 463 days, respectively. Negative prognostic factors for survival time determined via univariate analyses were histologic subtype and development of lung metastases. Telangiectatic or telangiectatic-mixed subtype (n = 5) was the only negative prognostic factor identified via multivariate analysis (median survival time, 208 days). Dogs with telangiectatic subtype were 6.99 times as likely to die of the disease. CONCLUSIONS AND CLINICAL RELEVANCE: The prognosis for ulnar osteosarcoma in this population was no worse and may have been better than the prognosis for dogs with osteosarcoma involving other appendicular sites. Partial ulnar ostectomy was associated with a low complication rate and good to excellent function and did not compromise survival time. Telangiectatic or telangiectatic-mixed histologic subtype was a negative prognostic factor for survival time. The efficacy of chemotherapy requires further evaluation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23786196/